By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


DelMar Pharmaceuticals 

999 West Broadway
Suite 720
  British Columbia  V5Z 1K5  Canada
Phone: 1-604-629-5989 Fax:



Company News
DelMar Pharmaceuticals Announces Upcoming Investor And Scientific Conference Presentations 5/27/2015 8:16:06 AM
DelMar Pharmaceuticals Announces Third Quarter Fiscal Year 2015 Financial Results And Provides Corporate Update 5/18/2015 10:41:13 AM
DelMar Pharmaceuticals To Present Additional Data On VAL-083 As A Potential Treatment For Temozolomide-Resistant GBM At AACR Advances In Brain Cancer Research Conference 5/7/2015 12:22:49 PM
DelMar Pharmaceuticals To Present Data Supporting The Development Of VAL-083 In Refractory Glioblastoma Multiforme And Non-Small Cell Lung Cancer At The ASCO Annual Meeting 4/30/2015 11:51:38 AM
DelMar Pharmaceuticals Presents Promising Preclinical Data On VAL-083's Potential To Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 4/20/2015 1:07:14 PM
DelMar Pharmaceuticals Presents Updated Clinical Data On Phase I/II Study Of VAL-083 In Refractory Glioblastoma Multiforme (GBM) 4/20/2015 8:46:52 AM
DelMar Pharmaceuticals Presents Positive Preclinical Data On Val-083 For Treatment Of Non-Small Cell Lung Cancer At AACR Annual Meeting 4/20/2015 8:44:21 AM
DelMar Pharmaceuticals Adds Fourth Clinical Trial Site In Phase I/II Multicenter Study Of VAL-083 For Recurrent Malignant Glioma 4/16/2015 6:28:00 AM
DelMar Pharmaceuticals Announces Panel Participation In Cancer Advance Boston Conference On April 14, 2015 4/7/2015 9:52:45 AM
DelMar Pharmaceuticals Appoints Biopharmaceutical Industry Veteran, Erich Mohr, Ph.D., R.Psych., To The Board Of Directors 4/1/2015 11:31:50 AM